Intismeran autogene

Intismeran autogene (V940/mRNA-4157) is a personalized mRNA cancer vaccine co-developed by Moderna and Merck. It uses each patient's own tumor DNA to design a custom vaccine that trains the immune system to recognize mutations unique to that tumor, then pairs that with pembrolizumab (Keytruda), Merck's checkpoint inhibitor. The Phase 2b melanoma readout (KEYNOTE-942, J Clin Oncol 2026 5-year update) showed a 49% reduction in recurrence or death and a 59% reduction in distant metastasis or death versus pembrolizumab alone, with no new safety signals [1]. On 2026-08-11 Merck and Moderna announced that the Phase 3 INTerpath-001 adjuvant melanoma trial (NCT05933577, n=1,137) met its RFS and DMFS primary endpoints, and full data were presented at the ESMO 2026 Presidential Symposium (HR 0.58 for RFS, p<0.001) [2][3]. A broader Phase 3 program continues in parallel across non-small cell lung cancer, renal cell carcinoma, and bladder cancer [4][5]. Intismeran is now on track to become the first approved personalized cancer vaccine, validating individualized mRNA as a therapeutic category beyond COVID. For Moderna, this is the lead non-COVID asset and the clearest path back to growth as COVID revenue continues to decline [6]. For Merck, it is a franchise extension on top of a Keytruda business that generated roughly $29.5B in 2024 [7].

Novel compound, not approved anywhere, but no longer purely investigational: the Phase 3 adjuvant melanoma readout (INTerpath-001, NCT05933577) is positive and a BLA submission in high-risk resected melanoma is now the next catalyst, likely in 2027 [2][3]. FDA granted Breakthrough Therapy Designation in February 2023 for adjuvant (post-surgery, intended to prevent recurrence) high-risk melanoma based on the KEYNOTE-942 Phase 2b data [8]. The 2026 J Clin Oncol 5-year update maintained the recurrence-free survival benefit (HR 0.44, 49% reduction), which was the pre-ESMO basis for the parallel Phase 3 expansion [1]. Moderna's economic exposure runs through its 50/50 cost and profit share with Merck, structured after Merck exercised its option on mRNA-4157 in October 2022 for $250M [9]. Non-melanoma Phase 3 program: V940-002/INTerpath-002 in adjuvant NSCLC (NCT06077760, n=868), V940-014 in high-risk stage I NSCLC (NCT07513376, n=876), and V940-009/INTerpath-009 in adjuvant NSCLC (NCT06623422, n=680) [4][5][10]. Phase 2 trials cover metastatic squamous NSCLC, bladder with BCG, and a second melanoma cohort [11][12][13]. Note: the original writeup conflated NCT06077760 with INTerpath-001; the correct melanoma Phase 3 identifier is NCT05933577.

Cancer cells accumulate DNA mutations that produce abnormal protein fragments the immune system has never seen before. These fragments, called neoantigens, could in principle flag cancer cells for destruction by T cells, but tumors evolve ways to hide them and to exhaust the T cells that might kill them. Intismeran autogene attacks that problem by making each patient's vaccine from scratch. Biopsy the tumor, sequence it against the patient's own germline DNA, computationally pick up to 34 of the mutations most likely to produce fragments that the patient's HLA molecules can display, and encode all of them into a single mRNA packaged in a lipid nanoparticle (the same delivery technology used for the COVID vaccines) [1]. Injected intramuscularly, the mRNA instructs the patient's own cells to make those neoantigen fragments, which teaches T cells to hunt tumor cells carrying the matching mutations. Pembrolizumab blocks PD-1, a brake on T cells, so the newly primed T cells can actually attack rather than being switched off by the tumor. A decade of neoantigen vaccine programs disappointed before KEYNOTE-942, and three technical choices appear to have mattered most for the difference. First, mRNA/LNP delivery allowed up to 34 neoantigens to be encoded in a single construct, substantially more than the 10-20 typical of peptide platforms, raising the odds that at least some encoded epitopes would actually be presented and recognized. Second, Moderna's neoantigen selection algorithm trained on patient-matched HLA class I and II prediction rather than class I alone, which broadens the induced T cell response to include CD4 help, and the 5-year KEYNOTE-942 translational data confirmed increased T-cell receptor clonality and novel clonotype expansion in the combination arm [1]. Third, the trial was a randomized controlled design layered on top of a checkpoint inhibitor that already works in the indication, so the vaccine only had to add incremental benefit rather than carry the whole therapeutic effect. Earlier programs were almost all single-arm with historical controls or added to non-working backbones.

The lead Phase 3 is V940-001/INTerpath-001 (NCT05933577), an adjuvant (post-surgical) trial in resected stage IIB-IV melanoma comparing intismeran autogene plus pembrolizumab against pembrolizumab alone in 1,137 patients, with recurrence-free survival as the primary endpoint. Primary readout met in August 2026, full data presented at ESMO 2026: HR 0.58 (95% CI 0.45-0.75, p<0.001) for RFS at 24.6 months median follow-up [2][3]. The NSCLC strategy splits across three Phase 3s: V940-002/INTerpath-002 (NCT06077760) in adjuvant NSCLC, V940-014 (NCT07513376) in high-risk stage I NSCLC enrolling 876 patients with disease-free survival as the primary endpoint, and V940-009/INTerpath-009 (NCT06623422) in adjuvant NSCLC with 680 patients, again DFS primary [4][5][10]. Phase 2 work includes V940-011/INTerpath-011 in bladder cancer with BCG (NCT06833073, n=308) using event-free survival (BCG is Bacillus Calmette-Guerin, a live attenuated mycobacterial preparation that has been the standard of care for high-risk non-muscle-invasive bladder cancer for decades), V940-013 in metastatic squamous NSCLC (NCT07221474, n=180) using PFS, and V940-012/INTerpath-012 in melanoma (NCT06961006, n=160) [11][12][13]. All non-melanoma trials are actively recruiting as of October 2026. This parallel-development strategy is made possible by Keytruda's existing approvals in each tumor type and by Merck's willingness to spend ahead of readout.

Our model estimates a 29% chance this drug is eventually approved. It starts from the historical base rate for Phase 3 drugs in this area (about 48%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by more secondary endpoints than usual, larger-than-typical enrollment for this phase, and the sponsor's strong record of getting drugs approved; it is held back by weak or limited earlier-phase results. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk: the Phase 3 INTerpath-001 effect (HR 0.58) was weaker than the Phase 2b 5-year follow-up (HR 0.44), consistent with the usual phenomenon that effect sizes shrink in larger confirmatory trials. Overall survival is not yet mature. The three parallel NSCLC Phase 3s and the renal and bladder programs still carry independent efficacy risk because neoantigen prediction has to work across a far more heterogeneous HLA background and a different tumor mutational burden profile than cutaneous melanoma. Operational risk: each dose requires tumor sequencing, neoantigen selection, GMP mRNA manufacturing, and shipment to the clinic within roughly 6 to 8 weeks of surgery. Running that pipeline across thousands of patients on multiple continents is a logistics problem no company has solved commercially. Delays can push patients out of the adjuvant window. Safety: the vaccine was reasonably well tolerated through 5-year KEYNOTE-942 follow-up with no new safety signals, injection site reactions and fatigue dominating adverse events and immune-related AEs similar to pembrolizumab alone [1]. The open question is whether rare autoimmune events emerge at commercial scale when millions of custom vaccines target private mutations. Commercial risk: per-patient manufacturing will likely price intismeran in the $150K to $300K range. Payers will scrutinize that if the mature OS signal is not convincing. Competition: BioNTech and Genentech's autogene cevumeran (BNT122) is the direct personalized-neoantigen competitor, with its own Phase 2 pancreatic data and expanding program [15]. Market risk: despite meeting both primary endpoints, Merck and Moderna shares fell on the ESMO 2026 presentation because the effect size disappointed buyside expectations seeded by a pre-presentation data leak [14].

Signal, not noise. KEYNOTE-942 was one of the strongest adjuvant readouts in modern oncology, and the INTerpath-001 Phase 3 confirmed the direction with HR 0.58 in a 1,137 patient trial. Near-term watch items are the BLA submission timing in melanoma (likely 2027), FDA review cadence, and OS maturity. The three NSCLC Phase 3s and the renal and bladder programs remain the next binary moments and are the key read-through for whether the melanoma result generalizes across tumor types. For Moderna, with COVID revenue declining 53% in 2024 and another 40% in 2025, intismeran is the clearest path back to growth and probably the single largest driver of the stock [6]. For Merck, intismeran is a Keytruda franchise extension that pushes combination therapy into the standard of care for high-risk resected tumors just as Keytruda approaches its US patent expiry in 2028. Check back after each Merck or Moderna quarterly update, any FDA submission announcement, and any ESMO or ASCO abstract listing involving V940 or INTerpath-labeled trials.

No revenue. Pre-approval investigational asset. For Merck, commercial read-through runs through Keytruda, which generated roughly $29.5B in 2024 revenue and is the single asset most exposed to the US composition-of-matter patent expiry in 2028 [7]. Biosimilar entry in major markets is contested through patent and formulation litigation but broadly expected by 2030 to 2032, making combination standard-of-care approvals before that window commercially critical. Intismeran plus pembrolizumab combinations, if approved, extend the Keytruda franchise beyond the small-molecule patent horizon by locking in combination standard of care. For Moderna, the stakes are more existential: total revenue declined 53% in 2024 and another 40% in 2025, driven almost entirely by COVID vaccine sales normalizing to a seasonal commercial market. Year-end 2025 cash and investments were $8.1B against ongoing operating losses, with a $600M initial draw on the company's $1.5B credit facility [6]. Intismeran is Moderna's lead non-COVID asset and its share of a positive melanoma launch (50/50 profit split with Merck) would be the first material non-COVID revenue line and the primary driver of whether the equity story returns to growth.